Drug intelligence / Profile preview

Black sea bass

Development stage: Unknown
Lead developer: Atlantic Fish Co
Modality: Recombinant Proteins and Enzymes
Administration: Percutaneous, Intradermal

Overview

Black sea bass is an allergenic extract derived from the fish species Centropristis striata, primarily used in allergy testing to detect sensitivity to this specific seafood. The extract is administered as part of diagnostic procedures for identifying IgE-mediated allergic reactions. Its mechanism of action involves provoking an immune response in individuals sensitized to proteins found in black sea bass, allowing clinicians to confirm or rule out allergies related to this fish[1][2][8].

Other names: Centropristis striata

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on Black sea bass.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Black sea bass.

Explore the full profile